Catalog No.
PAD12601
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Ranibizumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Lucentis.
Specificity
The product is specific for Ranibizumab. This antibody serves as an excellent positive control for Ranibizumab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 347396-82-1
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Ranibizumab with trade name Lucentis, is an FDA-approved drug for the treatment of patients with neovascular (Wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO). It is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment. Ranibizumab binds to vascular endothelial growth factor A (VEGF-A) and blocks its activity. Antibodysystem Anti-Ranibizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Ranibizumab.
Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review., PMID:40489855
Modeling the Ocular Pharmacokinetics and Pharmacodynamics of Ranibizumab for Improved Understanding and Data Collection Strategies in Ocular Diseases., PMID:40478563
EFFICACY AND PROGNOSIS OF ANTI-VEGF AGENTS COMBINED WITH PANRETINAL PHOTOCOAGULATION IN DIABETIC RETINOPATHY: A CLINICAL OBSERVATIONAL STUDY., PMID:40466685
Anti-VEGF Agents Clearance Through the Aqueous Outflow Pathway in a Rat Model., PMID:40455045
Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema., PMID:40455044
Targeting VEGF With 99mTc-Labeled Ranibizumab for Noninvasive Diagnosis of Non-Small Cell Lung Cancer., PMID:40444333
Area Under the Curve Analysis in a Real-World Cohort of Finnish Patients Treated for Neovascular Age-Related Macular Degeneration., PMID:40423616
Subretinal tissue plasminogen activator in polypoidal choroidal vasculopathy-related submacular haemorrhage and exudative retinal detachment., PMID:40409770
Efficacy and safety of prophylactic simultaneous intravitreal moxifloxacin injection with standard intravitreal anti-VEGF injection procedure in cases of cystoid macular edema and macular neovascularization., PMID:40405143
Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion., PMID:40405136
[Age-related macular degeneration - Part 2: therapeutic options for AMD]., PMID:40389215
Combining ranibizumab with calcium dobesilate to reduce injection frequency in diabetic macular edema treatment., PMID:40381058
[Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology]., PMID:40353548
Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy., PMID:40338383
Contributing factors to short-term intraocular pressure elevation following intravitreal anti-VEGF injections., PMID:40335957
Endophthalmitis following intravitreal injections at a tertiary center: real-life data on incidence, risk factors, management strategies, and visual outcomes., PMID:40335933
Visual fields after anti-vascular endothelial growth factor therapy for retinopathy of prematurity., PMID:40333931
Efficacy of ranibizumab with laser in the treatment of diabetic retinopathy compare with laser monotherapy: A systematic review and meta-analysis., PMID:40331557
Uncommon Therapeutic Approaches for Patients with Recurrent Central Serous Chorioretinopathy: case report and literature review., PMID:40330964
Predictive factors for adherence to intravitreal anti-vascular endothelial growth factor therapy in Palestinian patients with diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration: a retrospective cohort study., PMID:40329243
Real-world safety and efficacy of Anti-VEGF treatment in Brazil., PMID:40298749
Analysis of the etiology, clinical characteristics and treatment outcomes of choroidal neovascularization in Chinese children and adolescents., PMID:40295924
Short-term comparison of switching to faricimab from other anti-VEGF agents in neovascular age-related macular degeneration patients: A retrospective study., PMID:40295235
Radiomics Analysis Based on Optical Coherence Tomography to Prognose the Efficacy of Anti-VEGF Therapy of Retinal Vein Occlusion-Related Macular Edema., PMID:40277425
West Nile Virus Chorioretinitis: First Case with Ocular Involvement in Türkiye., PMID:40272218
The relationship between pain intensity and anxiety, injection speed, and intraocular pressure changes during intravitreal anti-vascular endothelial growth factor injection: the observational pilot study., PMID:40241022
Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes., PMID:40217902
Outcome of optic disc capillary hemangioma following intravitreal ranibizumab injection: A case report., PMID:40215408
[Morphological and functional changes of secondary macular neovascularization in central serous chorioretinopathy under anti-VEGF treatment]., PMID:40199756
Structural Updates to the Implant and Refill Needle of the Port Delivery Platform., PMID:40192619
The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy., PMID:40143057
SIRE: Short interval in real life Does intensive anti-VEGF treatment in the first year predict subsequent treatment burden in exudative age-related macular degeneration?, PMID:40114029
Two-year treatment outcomes after anti-vascular endothelial growth factor therapy in age-related macular degeneration with type 2 macular neovascularization in Japanese patients., PMID:40095326
Solution-Phase Kinetics of Ranibizumab Binding VEGF Using Solid-Phase Surface Plasmon Resonance., PMID:40094177
Association of plasma metabolites with treatment response after intravitreal anti-vascular endothelial growth factor injections in treatment-naïve neovascular age-related macular degeneration., PMID:40090700
Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment., PMID:40089567
Predictors of macular edema recurrence and visual outcomes in branch retinal vein occlusion treated with aflibercept or ranibizumab., PMID:40085265
Predictors of Visual Response After Lapse in Treatment Among Patients With Neovascular Age-related Macular Degeneration., PMID:40085093
Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan., PMID:40078048
Retinal sensitivity above macular neovascularization under anti-VEGF therapy in exudative neovascular age-related macular degeneration., PMID:40075283
Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial., PMID:40048197
Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial., PMID:40048178
Evaluating photodynamic therapy as an adjuvant treatment for neovascular AMD: A comprehensive meta-analysis., PMID:40037467
Longitudinal renal function changes during real-world anti-vascular endothelial growth factor therapy for diabetic macular edema in Japan., PMID:40019637
Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity., PMID:40016518
Faricimab-Associated Intraocular Inflammation With Features of Herpes Simplex Virus., PMID:40015591
[Bevacizumab in age-related macular degeneration: more injections, better vision, at lower costs]., PMID:40013669
Sozinibercept Combination Therapy for Neovascular Age-related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type., PMID:39999360
CHOROIDAL NEOVASCULARIZATION IN A CHILD WITH DOWN SYNDROME., PMID:39998939
Impact of photodynamic therapy combined with Anti-VEGF vs. Anti-VEGF monotherapy on choriocapillaris vessel density in polypoidal choroidal vasculopathy., PMID:39993696
For research use only. Not for human or drug use.
